Triple-negative breast cancer, so called because it lacks expression of the estrogen
receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast …

Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct
morphological features and clinical behaviors. Although morphology is often associated with …

Background Immunohistochemical markers are often used to classify breast cancer into
subtypes that are biologically distinct and behave differently. The aim of this study was to …

Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen
and progesterone receptor as well as human epidermal growth factor receptor 2. It is …

Breast cancer (BC) is a serious worldwide disease that threatens women's health.
Particularly, the morbidity of triple-negative breast cancer (TNBC) is higher than that of other …

Breast cancer is a heterogeneous disease that encompasses several distinct entities with
remarkably different biological characteristics and clinical behaviour. Currently, breast …

Background Triple‐negative breast cancer (TNBC) has been associated with a more
aggressive histology, poorer prognosis, and nonresponsiveness to hormone therapy. It is …

Background Clinical experience suggests that many women with triple-negative metastatic
breast cancer (MBC) relapse quickly. This has implications for clinical practice and trial …

Purpose: Previous research identified differences in breast cancer–specific mortality across
4 intrinsic tumor subtypes: luminal A, luminal B, basal-like, and human epidermal growth …

Molecular subty** of breast cancer may provide additional prognostic information
regarding patient outcome. However, its clinical significance remains to be established. In …